GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CBAN · Sep 30, 2024

COLONY BANKCORP INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000711669-24-000128Bank
Sequential deposit growth60thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

2.63% · CORE · VALID

Net-income growth30thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

-3.02% · CORE · VALID

Interest-income growth25thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

6.22% · CORE · VALID

Cash and equivalents55thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$144.9M · CORE · VALID

Sequential loan growth30thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

1.06% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History60 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Increased
Previous
-2.48%
Current
2.63%
Delta
5.11%
Earnings Growth Decreased
Previous
3.24%
Current
-3.02%
Delta
-6.26%
Interest Income Growth Decreased
Previous
8.36%
Current
6.22%
Delta
-2.14%
Liquidity Increased
Previous
$82.0M
Current
$144.9M
Delta
$62.9M
Loan Growth Increased
Previous
0.35%
Current
1.06%
Delta
0.71%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.